Article
In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer.
PloS one - 1 Jan 2017
Tashiro Takahiro, Okuyama Hiroaki, Endo Hiroko, Kawada Kenji, Ashida Yasuko, Ohue Masayuki, Sakai Yoshiharu, Inoue Masahiro
Abstract excerpt
In clinic, cetuximab, an anti-EGFR antibody, improves treatment outcomes in colorectal cancer (CRC). KRAS-mutant CRC is generally resistant to cetuximab, although difference of the sensitivity among KRAS-mutants has not been studied in detail. We previously developed the cancer tissue-originated spheroid (CTOS) method, a primary culture method for cancer cells. We applied CTOS method to investigate whether ex...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.